NI201100170A - Inhibidores de epoxicetonas proteasa de tripéptidos cristalinos - Google Patents
Inhibidores de epoxicetonas proteasa de tripéptidos cristalinosInfo
- Publication number
- NI201100170A NI201100170A NI201100170A NI201100170A NI201100170A NI 201100170 A NI201100170 A NI 201100170A NI 201100170 A NI201100170 A NI 201100170A NI 201100170 A NI201100170 A NI 201100170A NI 201100170 A NI201100170 A NI 201100170A
- Authority
- NI
- Nicaragua
- Prior art keywords
- epoxycetone
- inhibitors
- crystalline tripeptide
- protease
- crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
- C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
Abstract
La invención se refiere a compuestos ceto epóxido de tripéptidos cristalinos, a métodos para su preparación y a composiciones farmacéuticas relacionadas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16219609P | 2009-03-20 | 2009-03-20 | |
US18056109P | 2009-05-22 | 2009-05-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
NI201100170A true NI201100170A (es) | 2012-02-21 |
Family
ID=42738216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NI201100170A NI201100170A (es) | 2009-03-20 | 2011-09-20 | Inhibidores de epoxicetonas proteasa de tripéptidos cristalinos |
Country Status (45)
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1948678T3 (pl) | 2005-11-09 | 2013-09-30 | Onyx Therapeutics Inc | Związki do hamowania enzymów |
SI2041158T1 (sl) | 2006-06-19 | 2013-09-30 | Onyx Therapeutics, Inc. | Peptidni epoksiketoni za inhibicijo proteasomov |
US8367617B2 (en) | 2007-10-04 | 2013-02-05 | Onyx Therapeutics, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
JP5675629B2 (ja) | 2008-10-21 | 2015-02-25 | オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. | ペプチドエポキシケトンを用いた併用療法 |
AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
HUE029892T2 (en) | 2009-10-07 | 2017-04-28 | Dow Agrosciences Llc | Synergistic fungicidal preparations for fungi in cereals |
EP2498793B1 (en) | 2009-11-13 | 2019-07-10 | Onyx Therapeutics, Inc. | Oprozomib for use in metastasis suppression |
MX2012010017A (es) | 2010-03-01 | 2012-10-01 | Onyx Therapeutics Inc | Compuestos de para la inhibicion de inmunoproteasomas. |
MX2012011604A (es) | 2010-04-07 | 2013-02-27 | Onyx Therapeutics Inc | Inhibidor de inmunoproteasoma de péptido epoxicetona cristalino. |
US9309283B2 (en) | 2012-07-09 | 2016-04-12 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
JP6187779B2 (ja) * | 2012-08-10 | 2017-08-30 | 味の素株式会社 | γ−グルタミルバリルグリシン結晶の製造方法 |
TW201422255A (zh) * | 2012-10-24 | 2014-06-16 | Onyx Therapeutics Inc | 用於蛋白酶體抑制劑之調整釋放製劑 |
KR102148190B1 (ko) | 2012-12-28 | 2020-08-26 | 다우 아그로사이언시즈 엘엘씨 | 곡류에서의 진균 방제를 위한 상승작용적 살진균 혼합물 |
CN106028814A (zh) | 2013-12-26 | 2016-10-12 | 美国陶氏益农公司 | 大环吡啶酰胺作为杀真菌剂的用途 |
CN104945470B (zh) * | 2014-03-30 | 2020-08-11 | 浙江大学 | 杂环构建的三肽环氧酮类化合物及制备和应用 |
CN104974221B (zh) * | 2014-04-03 | 2020-10-23 | 中国医学科学院药物研究所 | 二肽及三肽类蛋白酶体抑制剂及其制法和药物用途 |
US9955691B2 (en) | 2014-07-08 | 2018-05-01 | Dow Agrosciences Llc | Macrocyclic picolinamides as fungicides |
US20160115198A1 (en) | 2014-10-27 | 2016-04-28 | Apicore Us Llc | Methods of making carfilzomib and intermediates thereof |
AU2015374376B2 (en) * | 2014-12-30 | 2018-02-15 | Dow Agrosciences Llc | Picolinamides with fungicidal activity |
ES2841906T3 (es) | 2014-12-30 | 2021-07-12 | Dow Agrosciences Llc | Picolinamidas como fungicidas |
BR112017013676A2 (pt) | 2014-12-30 | 2018-01-09 | Dow Agrosciences Llc | uso de compostos de picolinamida como fungicidas |
JP6742319B2 (ja) | 2014-12-30 | 2020-08-19 | ダウ アグロサイエンシィズ エルエルシー | 殺真菌活性を有するピコリンアミド化合物 |
CA2972403A1 (en) | 2014-12-30 | 2016-07-07 | Dow Agrosciences Llc | Picolinamide compounds with fungicidal activity |
CN105949279A (zh) * | 2016-04-27 | 2016-09-21 | 浙江大学 | 蛋白酶体抑制剂Oprozomib及其类似物的制备方法 |
BR112018077390A2 (pt) | 2016-06-29 | 2019-04-09 | Kezar Life Sciences | sais cristalinos de peptídeo epoxicentona inibidor de imunoproteassoma |
CN109641860B (zh) | 2016-06-29 | 2024-05-28 | 科智生命科学公司 | 制备肽环氧酮免疫蛋白酶体抑制剂和其前体的方法 |
WO2018045012A1 (en) | 2016-08-30 | 2018-03-08 | Dow Agrosciences Llc | Pyrido-1,3-oxazine-2,4-dione compounds with fungicidal activity |
US10173982B2 (en) | 2016-08-30 | 2019-01-08 | Dow Agrosciences Llc | Picolinamides as fungicides |
US10111432B2 (en) | 2016-08-30 | 2018-10-30 | Dow Agrosciences Llc | Picolinamide N-oxide compounds with fungicidal activity |
US10231452B2 (en) | 2016-08-30 | 2019-03-19 | Dow Agrosciences Llc | Thiopicolinamide compounds with fungicidal activity |
JP2019529458A (ja) | 2016-09-21 | 2019-10-17 | 小野薬品工業株式会社 | オプロゾミブ用の即放性製剤 |
JP2018123119A (ja) | 2016-12-14 | 2018-08-09 | アムジエン・インコーポレーテツド | オプロゾミブのための胃内保持型の徐放性剤形、及びその調製プロセス |
BR102018000183B1 (pt) | 2017-01-05 | 2023-04-25 | Dow Agrosciences Llc | Picolinamidas, composição para controle de um patógeno fúngico, e método para controle e prevenção de um ataque por fungos em uma planta |
TWI774761B (zh) | 2017-05-02 | 2022-08-21 | 美商科迪華農業科技有限責任公司 | 用於穀物中的真菌防治之協同性混合物 |
CN110996665B (zh) | 2017-05-02 | 2021-10-26 | 陶氏益农公司 | 无环吡啶酰胺化合物作为针对草坪草上的真菌病害的杀真菌剂的用途 |
TW201842851A (zh) | 2017-05-02 | 2018-12-16 | 美商陶氏農業科學公司 | 用於穀類中的真菌防治之協同性混合物 |
JP2020533382A (ja) | 2017-09-14 | 2020-11-19 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 癌の組合せ治療 |
BR102019004480B1 (pt) | 2018-03-08 | 2023-03-28 | Dow Agrosciences Llc | Picolinamidas como fungicidas |
US11639334B2 (en) | 2018-10-15 | 2023-05-02 | Corteva Agriscience Llc | Methods for synthesis of oxypicolinamides |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US5135919A (en) | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
US5441944A (en) | 1989-04-23 | 1995-08-15 | The Trustees Of The University Of Pennsylvania | Substituted cyclodextrin sulfates and their uses as growth modulating agents |
US4990448A (en) | 1989-08-04 | 1991-02-05 | Bristol-Myers Company | Bu-4061T |
US5071957A (en) | 1989-08-04 | 1991-12-10 | Bristol-Myers Company | Antibiotic BU-4061T |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
CA2077665A1 (en) | 1990-03-05 | 1991-09-06 | Robert Siman | Chymotrypsin-like proteases and their inhibitors |
US5561134A (en) * | 1990-09-25 | 1996-10-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
US5340736A (en) | 1991-05-13 | 1994-08-23 | The President & Fellows Of Harvard College | ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting |
EP0955365A3 (en) * | 1992-06-09 | 2000-12-20 | Chiron Corporation | Crystallization of M-CSF |
GB9300048D0 (en) * | 1993-01-04 | 1993-03-03 | Wellcome Found | Endothelin converting enzyme inhibitors |
TW380137B (en) | 1994-03-04 | 2000-01-21 | Merck & Co Inc | Process for making an epoxide |
US5693617A (en) | 1994-03-15 | 1997-12-02 | Proscript, Inc. | Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein |
US6660268B1 (en) | 1994-03-18 | 2003-12-09 | The President And Fellows Of Harvard College | Proteasome regulation of NF-KB activity |
US6506876B1 (en) | 1994-10-11 | 2003-01-14 | G.D. Searle & Co. | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use |
US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
DE19505263A1 (de) | 1995-02-16 | 1996-08-22 | Consortium Elektrochem Ind | Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten |
US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
US6150415A (en) | 1996-08-13 | 2000-11-21 | The Regents Of The University Of California | Epoxide hydrolase complexes and methods therewith |
WO1998010779A1 (en) | 1996-09-13 | 1998-03-19 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
UA79749C2 (en) | 1996-10-18 | 2007-07-25 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
EP1136498A1 (en) | 1996-10-18 | 2001-09-26 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus NS3 protease |
US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
PT986403E (pt) | 1997-06-13 | 2004-04-30 | Cydex Inc | Composicao com um tempo de vida de armazenagem prolongado compreendendo a ciclodextrina e drogas ou prodrogas que se decompoem em compostos insoluveis em agua |
US6133308A (en) | 1997-08-15 | 2000-10-17 | Millennium Pharmaceuticals, Inc. | Synthesis of clasto-lactacystin beta-lactone and analogs thereof |
US6100282A (en) * | 1998-01-02 | 2000-08-08 | Hoffman-La Roche Inc. | Thiazole derivatives |
US6075150A (en) | 1998-01-26 | 2000-06-13 | Cv Therapeutics, Inc. | α-ketoamide inhibitors of 20S proteasome |
US6099851A (en) | 1998-06-02 | 2000-08-08 | Weisman; Kenneth M. | Therapeutic uses of leuprolide acetate |
US6462019B1 (en) | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
US6902721B1 (en) | 1998-07-10 | 2005-06-07 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6838436B1 (en) | 1998-07-10 | 2005-01-04 | Osteoscreen Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6204257B1 (en) | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
WO2000023614A1 (en) | 1998-10-20 | 2000-04-27 | Millennium Pharmaceuticals, Inc. | Method for monitoring proteasome inhibitor drug action |
US6492333B1 (en) | 1999-04-09 | 2002-12-10 | Osteoscreen, Inc. | Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors |
US6831099B1 (en) | 1999-05-12 | 2004-12-14 | Yale University | Enzyme inhibition |
US6114365A (en) * | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
AU784304B2 (en) | 1999-10-20 | 2006-03-09 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
ATE338564T1 (de) | 2000-10-12 | 2006-09-15 | Viromics Gmbh | Proteasome inhibitoren zur behandlung von hepatitis-virus infektionen |
GB0114185D0 (en) * | 2001-06-12 | 2001-08-01 | Protherics Molecular Design Lt | Compounds |
DK1355910T3 (da) | 2001-01-25 | 2011-06-27 | Us Of America Represented By The Secretary Dept Of Health And Human Services | Formulering af borsyreforbindelser |
DE60218153T2 (de) | 2001-05-21 | 2007-06-28 | Alcon Inc. | Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges |
EP1463719A2 (en) | 2002-01-08 | 2004-10-06 | Eisai Co., Ltd | Eponemycin and epoxomicin analogs and uses thereof |
US20040116329A1 (en) | 2002-01-29 | 2004-06-17 | Epstein Stephen E. | Inhibition of proteasomes to prevent restenosis |
AU2003220685A1 (en) | 2002-04-09 | 2003-10-27 | Greenville Hospital System | Metastasis modulating activity of highly sulfated oligosaccharides |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7902185B2 (en) | 2002-06-03 | 2011-03-08 | Als Therapy Development Foundation, Inc. | Treatment of neurodegenerative diseases using proteasome modulators |
US20030224469A1 (en) | 2002-06-03 | 2003-12-04 | Buchholz Tonia J. | Methods and kits for assays utilizing fluorescence polarization |
WO2004010937A2 (en) | 2002-07-26 | 2004-02-05 | Advanced Research & Technology Institute At Indiana University | Method of treating cancer |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
TW200418791A (en) | 2003-01-23 | 2004-10-01 | Bristol Myers Squibb Co | Pharmaceutical compositions for inhibiting proteasome |
DE122011100047I1 (de) | 2003-04-08 | 2011-12-15 | Mitsubishi Tanabe Pharma Corp | Feste pharmazeutische darreichungsformen mit einemS1P rezeptoragonisten und einem zuckeralkohol. |
JP4653103B2 (ja) | 2003-06-10 | 2011-03-16 | ザ ジェイ.ディヴィッド グラッドストン インスティテューツ | レンチウイルス感染症を治療するための方法 |
US7012063B2 (en) | 2003-06-13 | 2006-03-14 | Children's Medical Center Corporation | Reducing axon degeneration with proteasome inhibitors |
MX348041B (es) | 2003-12-31 | 2017-05-25 | Cydex Pharmaceuticals Inc | Formulación inhalante que contiene éter sulfoalquilico-ciclodextri na y un corticosteroide. |
GB0400804D0 (en) | 2004-01-14 | 2004-02-18 | Innoscience Technology Bv | Pharmaceutical compositions |
US20050228031A1 (en) * | 2004-04-13 | 2005-10-13 | Bilodeau Mark T | Tyrosine kinase inhibitors |
WO2005105827A2 (en) | 2004-04-15 | 2005-11-10 | Proteolix, Inc. | Compounds for proteasome enzyme inhibition |
US8198270B2 (en) | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
WO2005111009A2 (en) | 2004-05-10 | 2005-11-24 | Proteolix, Inc. | Synthesis of amino acid keto-epoxides |
US8088741B2 (en) | 2004-05-10 | 2012-01-03 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
ES2359004T3 (es) * | 2004-08-06 | 2011-05-17 | Onyx Therapeutics, Inc. | Compuestos para inhibición enzimática de proteasoma. |
WO2006045066A2 (en) | 2004-10-20 | 2006-04-27 | Proteolix, Inc. | Labeled compounds for proteasome inhibition |
HUE027850T2 (en) | 2004-12-07 | 2016-11-28 | Onyx Therapeutics Inc | Preparation for proteasome inhibition |
US7468383B2 (en) | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
EP1863513A2 (en) | 2005-03-11 | 2007-12-12 | The University of North Carolina at Chapel Hill | Potent and specific immunoproteasome inhibitors |
US7998938B2 (en) | 2005-04-15 | 2011-08-16 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
GT200600350A (es) | 2005-08-09 | 2007-03-28 | Formulaciones líquidas | |
PL1948678T3 (pl) | 2005-11-09 | 2013-09-30 | Onyx Therapeutics Inc | Związki do hamowania enzymów |
AR057227A1 (es) | 2005-12-09 | 2007-11-21 | Centocor Inc | Metodo para usar antagonistas de il6 con inhibidores del proteasoma |
US20070207950A1 (en) | 2005-12-21 | 2007-09-06 | Duke University | Methods and compositions for regulating HDAC6 activity |
WO2007122686A1 (ja) | 2006-04-14 | 2007-11-01 | Eisai R & D Management Co., Ltd. | ベンズイミダゾール化合物 |
DE102006026464A1 (de) | 2006-06-01 | 2007-12-06 | Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma | Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus |
SI2041158T1 (sl) | 2006-06-19 | 2013-09-30 | Onyx Therapeutics, Inc. | Peptidni epoksiketoni za inhibicijo proteasomov |
WO2008033807A2 (en) | 2006-09-13 | 2008-03-20 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Synergistic combinations of antineoplastic thiol-binding mitochondrial oxidants and antineoplastic proteasome inhibitors for the treatment of cancer |
US8601054B2 (en) * | 2006-12-07 | 2013-12-03 | International Business Machines Corporation | Project-related communications |
WO2008091620A2 (en) | 2007-01-23 | 2008-07-31 | Gloucester Pharmaceuticals, Inc. | Combination therapy comprising romidepsin and i.a. bortezomib |
WO2008140782A2 (en) * | 2007-05-10 | 2008-11-20 | Proteolix, Inc. | Compounds for enzyme inhibition |
US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
SG10201508712QA (en) | 2007-08-06 | 2015-11-27 | Millenium Pharmaceuticals Inc | Proteasome inhibitors |
US8367617B2 (en) * | 2007-10-04 | 2013-02-05 | Onyx Therapeutics, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
US7838673B2 (en) | 2007-10-16 | 2010-11-23 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
EP2212334B1 (en) | 2007-10-16 | 2012-08-15 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
US20090131367A1 (en) | 2007-11-19 | 2009-05-21 | The Regents Of The University Of Colorado | Combinations of HDAC Inhibitors and Proteasome Inhibitors |
EP2733147A1 (en) | 2008-06-17 | 2014-05-21 | Millennium Pharmaceuticals, Inc. | Boronate ester compounds and pharmaceutical compositions thereof |
AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
JP5675629B2 (ja) | 2008-10-21 | 2015-02-25 | オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. | ペプチドエポキシケトンを用いた併用療法 |
AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
CN101928329B (zh) | 2009-06-19 | 2013-07-17 | 北京大学 | 三肽硼酸(酯)类化合物、其制备方法和应用 |
EP2498793B1 (en) | 2009-11-13 | 2019-07-10 | Onyx Therapeutics, Inc. | Oprozomib for use in metastasis suppression |
MX2012010017A (es) | 2010-03-01 | 2012-10-01 | Onyx Therapeutics Inc | Compuestos de para la inhibicion de inmunoproteasomas. |
KR20130036228A (ko) | 2010-03-31 | 2013-04-11 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 1-아미노-2-사이클로프로필에틸보론산의 유도체 |
MX2012011604A (es) | 2010-04-07 | 2013-02-27 | Onyx Therapeutics Inc | Inhibidor de inmunoproteasoma de péptido epoxicetona cristalino. |
-
2010
- 2010-03-19 AR ARP100100894A patent/AR075899A1/es unknown
- 2010-03-19 TW TW099108136A patent/TWI504598B/zh not_active IP Right Cessation
- 2010-03-20 SA SA110310221A patent/SA110310221B1/ar unknown
- 2010-03-20 SA SA114350283A patent/SA114350283B1/ar unknown
- 2010-03-22 ES ES14178725.9T patent/ES2614557T3/es active Active
- 2010-03-22 NZ NZ61843210A patent/NZ618432A/en not_active IP Right Cessation
- 2010-03-22 PT PT141787259T patent/PT2813241T/pt unknown
- 2010-03-22 SI SI201030833T patent/SI2408758T1/sl unknown
- 2010-03-22 SG SG2014011373A patent/SG2014011373A/en unknown
- 2010-03-22 DK DK10754225.0T patent/DK2408758T3/da active
- 2010-03-22 GE GEAP201012421A patent/GEP20156392B/en unknown
- 2010-03-22 MX MX2013012107A patent/MX343562B/es unknown
- 2010-03-22 MA MA34254A patent/MA33197B1/fr unknown
- 2010-03-22 SI SI201031354A patent/SI2813241T1/sl unknown
- 2010-03-22 PE PE2011001673A patent/PE20120645A1/es active IP Right Grant
- 2010-03-22 CA CA2755971A patent/CA2755971C/en not_active Expired - Fee Related
- 2010-03-22 WO PCT/US2010/028126 patent/WO2010108172A1/en active Application Filing
- 2010-03-22 EP EP10754225.0A patent/EP2408758B1/en active Active
- 2010-03-22 SG SG2011067204A patent/SG174446A1/en unknown
- 2010-03-22 EP EP14178725.9A patent/EP2813241B1/en active Active
- 2010-03-22 MY MYPI2011004414A patent/MY156522A/en unknown
- 2010-03-22 DK DK14178725.9T patent/DK2813241T3/en active
- 2010-03-22 BR BRPI1009369A patent/BRPI1009369A2/pt not_active Application Discontinuation
- 2010-03-22 US US13/257,887 patent/US8604215B2/en not_active Expired - Fee Related
- 2010-03-22 ES ES10754225.0T patent/ES2527619T3/es active Active
- 2010-03-22 JP JP2012501028A patent/JP5723357B2/ja active Active
- 2010-03-22 CN CN201080021879.8A patent/CN102428075B/zh not_active Expired - Fee Related
- 2010-03-22 PL PL10754225T patent/PL2408758T3/pl unknown
- 2010-03-22 MX MX2011009777A patent/MX2011009777A/es active IP Right Grant
- 2010-03-22 KR KR1020117022814A patent/KR101729344B1/ko active IP Right Grant
- 2010-03-22 AU AU2010226410A patent/AU2010226410B2/en not_active Ceased
- 2010-03-22 EA EA201171151A patent/EA020973B1/ru not_active IP Right Cessation
- 2010-03-22 NZ NZ595847A patent/NZ595847A/en not_active IP Right Cessation
- 2010-03-22 HU HUE14178725A patent/HUE032430T2/en unknown
- 2010-03-22 RS RS20161122A patent/RS55431B1/sr unknown
- 2010-03-22 PL PL14178725T patent/PL2813241T3/pl unknown
- 2010-03-22 RS RS20150015A patent/RS53746B1/en unknown
- 2010-03-22 EA EA201300860A patent/EA024672B1/ru not_active IP Right Cessation
- 2010-03-22 PT PT107542250T patent/PT2408758E/pt unknown
- 2010-03-22 AP AP2013007137A patent/AP3513A/xx active
- 2010-03-22 ME MEP-2011-164A patent/ME01277B/me unknown
- 2010-03-22 LT LTEP14178725.9T patent/LT2813241T/lt unknown
- 2010-03-22 US US12/728,547 patent/US20100240903A1/en not_active Abandoned
-
2011
- 2011-09-15 IL IL215174A patent/IL215174A/en not_active IP Right Cessation
- 2011-09-16 DO DO2011000286A patent/DOP2011000286A/es unknown
- 2011-09-16 CO CO11120506A patent/CO6430433A2/es not_active Application Discontinuation
- 2011-09-19 ZA ZA2011/06826A patent/ZA201106826B/en unknown
- 2011-09-19 TN TN2011000470A patent/TN2011000470A1/fr unknown
- 2011-09-19 CR CR20110491A patent/CR20110491A/es unknown
- 2011-09-20 EC EC2011011341A patent/ECSP11011341A/es unknown
- 2011-09-20 CU CU20110176A patent/CU20110176A7/es unknown
- 2011-09-20 US US13/237,655 patent/US8822512B2/en not_active Expired - Fee Related
- 2011-09-20 CL CL2011002326A patent/CL2011002326A1/es unknown
- 2011-09-20 HN HN2011002459A patent/HN2011002459A/es unknown
- 2011-09-20 NI NI201100170A patent/NI201100170A/es unknown
-
2012
- 2012-03-15 HK HK12102641.5A patent/HK1162476A1/xx not_active IP Right Cessation
-
2013
- 2013-09-24 US US14/035,644 patent/US9051353B2/en not_active Expired - Fee Related
-
2015
- 2015-01-08 HR HRP20150014AT patent/HRP20150014T1/hr unknown
- 2015-01-12 SM SM201500009T patent/SMT201500009B/xx unknown
- 2015-03-05 US US14/639,603 patent/US9403868B2/en not_active Expired - Fee Related
- 2015-06-16 HK HK15105658.5A patent/HK1204952A1/xx not_active IP Right Cessation
-
2016
- 2016-03-11 ZA ZA2016/01686A patent/ZA201601686B/en unknown
- 2016-12-06 HR HRP20161654TT patent/HRP20161654T1/hr unknown
- 2016-12-16 CY CY20161101307T patent/CY1118359T1/el unknown
-
2017
- 2017-01-30 SM SM201700068T patent/SMT201700068B/it unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201100170A (es) | Inhibidores de epoxicetonas proteasa de tripéptidos cristalinos | |
CY1119245T1 (el) | Φαρμακευτικη συνθεση καρβετοκινης | |
CO6630130A2 (es) | Inhibidor de inmunoproteasoma de péptido epoxicetona cristalino | |
EA201101026A1 (ru) | Ингибиторы бета-секретазы | |
ECSP12011581A (es) | Inhibidores de bace | |
UY33735A (es) | Compuestos antivirales | |
BRPI1012638B8 (pt) | métodos e intermediários para preparar agentes farmacêuticos | |
BRPI1013822A2 (pt) | Método para síntese de um trissacarídeo. | |
DK3192500T3 (da) | Sammensætninger til kontinuerlig indgivelse af dopa-decarboxylasehæmmere | |
MY162411A (en) | Crystalline forms of a macrolide, and uses therefor | |
DK3354657T3 (da) | Fremgangsmåde til fremstilling af planteafledte proteiner | |
CL2012000590A1 (es) | Proceso para preparar w-transaminasa (r)-selectiva. | |
EA201290772A1 (ru) | Новые формы ивабрадина гидрохлорида | |
DK2508083T3 (da) | Biologisk aktivt kosttilskud til profylakse af osteoporose sygdomme | |
UA111142C2 (uk) | Одержання заміщених похідних 2-фторакрилової кислоти | |
DK2493312T3 (da) | Farmaceutiske faststofsammensætninger, der indeholder en integrase- hæmmer | |
CL2012003491A1 (es) | Compuesto derivado de dihidropirrol sustituidos; proceso para preparar dichos derivados en forma estereoselectiva. | |
IT1397255B1 (it) | Struttura di impianto dentale perfezionato. | |
BR112012001340A2 (pt) | composições farmacêuticas | |
IT1399148B1 (it) | Impianto per la realizzazione di artocoli igienici intimi. | |
FR2961209B1 (fr) | Procede de synthese de la ferroquine par amination reductrice convergente. | |
CL2008001014A1 (es) | Procedimiento para preparar comprimidos de dihidrocloruro de prampipexol. | |
CR20120169A (es) | Procesos para la preparación de 2-(1-feniletil)-isoindolin-1-ona | |
FR2967164B1 (fr) | Procede de preparation de compositions a base de polypentosides | |
MX2010003056A (es) | Polimorfos de valomaciclovir. |